Table 2.
Baseline characteristics among patients receiving mTEG according to PPI use before and after PSM
| Parameters | Before PSM | After PSM | ||||||
|---|---|---|---|---|---|---|---|---|
| PPI (n = 1368) | No PPI (n = 3674) | Statistics | P | PPI (n = 1297) | No PPI (n = 1297) | Statistics | P | |
| Demographics | ||||||||
| Gender (female) | 341 (24.9) | 721 (19.6) | 16.857* | <0.001 | 324 (25.0) | 260 (20.0) | 9.052* | 0.003 |
| Age (years) | 59.9 ± 10.5 | 57.6 ± 10.3 | −7.145† | <0.001 | 59.9 ± 10.6 | 59.1 ± 10.5 | −2.0368† | 0.042 |
| Past medical history | ||||||||
| Hypertension | 890 (65.1) | 2343 (63.8) | 0.746* | 0.388 | 849 (65.5) | 854 (65.8) | 0.043* | 0.839 |
| Dyslipidemia | 916 (67.0) | 2507 (68.2) | 1.453* | 0.228 | 869 (67.0) | 879 (67.8) | 0.175* | 0.675 |
| Diabetes mellitus | 409 (29.9) | 1124 (30.6) | 0.228* | 0.633 | 394 (30.4) | 388 (29.9) | 0.066* | 0.797 |
| PAD | 48 (3.5) | 94 (2.6) | 3.289* | 0.070 | 46 (3.5) | 37 (2.9) | 1.008* | 0.315 |
| Prior CVD | 187 (13.7) | 342 (9.3) | 20.187* | <0.001 | 175 (13.5) | 179 (138) | 0.052* | 0.819 |
| Prior MI | 279 (20.4) | 1035 (28.2) | 31.282* | <0.001 | 263 (20.3) | 277 (21.4) | 0.458* | 0.498 |
| Prior PCI | 352 (25.7) | 1062 (28.9) | 4.979* | 0.026 | 317 (24.4) | 335 (25.8) | 0.664* | 0.415 |
| Prior CABG | 63 (4.6) | 171 (4.7) | 0.005* | 0.941 | 61 (4.7) | 62 (4.8) | 0.009* | 0.926 |
| Admission features | ||||||||
| Acute MI | 300 (21.9) | 698 (19.0) | 5.396* | 0.020 | 267 (20.6) | 228 (17.6) | 3.797* | 0.051 |
| LVEF (%) | 62.0 ± 7.8 | 62.4 ± 7.5 | 1.607† | 0.108 | 62.2 ± 7.6 | 62.4 ± 7.5 | 0.587† | 0.557 |
| Killip class ≥2 | 19 (1.4) | 30 (0.8) | 3.393* | 0.065 | 15 (1.2) | 14 (1.1) | 0.035* | 0.852 |
| SAP (mmHg) | 126.2 ± 17.3 | 126.5 ± 16.7 | 0.641† | 0.522 | 126.3 ± 17.3 | 127.3 ± 16.9 | 1.564† | 0.118 |
| Current smoking | 783 (57.2) | 2151 (58.5) | 0.703* | 0.402 | 738 (56.9) | 749 (57.7) | 0.191* | 0.662 |
| Laboratory test | ||||||||
| BNP (pg/ml) | 648.8 (474.6–909.2) | 615.7 (480.5–843.6) | −2.030‡ | 0.042 | 646.4 (474.1–911.6) | 610.6 (480.6–842.5) | −1.832‡ | 0.067 |
| eGFR (ml/min) | 89.6 ± 15.4 | 92.2 ± 14.7 | 5.408† | <0.001 | 89.6 ± 15.4 | 90.4 ± 15.1 | 1.354† | 0.176 |
| ESR (mm/h) | 7 (4–16) | 7 (3–14) | −2.983‡ | 0.003 | 7 (4–16) | 7 (3–13) | −3.795‡ | <0.001 |
| Hemoglobin (g/L) | 140.9 ± 15.9 | 144.2 ± 14.8 | 6.553† | <0.001 | 140.9 ± 15.9 | 144.3 ± 16.0 | 5.472† | <0.001 |
| Procedural characteristics | ||||||||
| Thrombolysis | 50 (3.7) | 134 (3.6) | <0.001* | 0.990 | 49 (3.8) | 50 (3.9) | 0.011* | 0.918 |
| Syntax score | ||||||||
| 0–22 | 1188 (86.8) | 3233 (88.0) | 1.615* | 0.446 | 1129 (87.0) | 1143 (88.1) | 0.796* | 0.672 |
| 23–32 | 153 (11.2) | 383 (10.4) | 143 (11.0) | 133 (10.3) | ||||
| ≥33 | 27 (2.0) | 58 (1.6) | 25 (1.9) | 21 (1.6) | ||||
| Number of stents | ||||||||
| 0 | 80 (5.8) | 207 (5.6) | 1.055* | 0.590 | 72 (5.6) | 66 (5.1) | 0.279* | 0.870 |
| 1 | 512 (37.48) | 1433 (39.0) | 485 (37.4) | 486 (37.5) | ||||
| ≥2 | 776 (56.7) | 2034 (55.4) | 740 (57.1) | 745 (57.4) | ||||
| IABP | 29 (2.1) | 36 (1.0) | 10.181* | 0.001 | 21 (1.6) | 19 (1.5) | 0.102* | 0.750 |
| Medication | ||||||||
| Warfarin | 2 (0.1) | 6 (0.2) | 0.018* | 0.892 | 2 (0.1) | 4 (0.3) | 0.668* | 0.414 |
| GPI | 222 (16.2) | 604 (16.4) | 0.033* | 0.857 | 202 (15.6) | 233 (18.0) | 2.654* | 0.103 |
Data are presented as n (%), mean ± SD or median (interquartile range). *χ2 values; †t values; ‡z value. PPI: Proton-pump inhibitors; mTEG: Modified thromboelastograph; PSM: Propensity score matching; PAD: Peripheral artery disease; CVD: Cerebrovascular disease; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass grafting; LVEF: Left ventricular ejection fraction; SAP: Systolic blood pressure; BNP: Brain natriuretic peptide; eGFR: Estimated glomerular filtration rate; ESR: Erythrocyte sedimentation rate; IABP: Intra-aortic balloon pump; GPI: Glycoprotein IIb/IIIa inhibitors; SD: Standard deviation; 1 mmHg=0.133 kPa.